In the present study, we investigated whether a combination of the AURKA inhibitor MK-5108 and the MEK inhibitor trametinib shows a synergistic antitumor effect in colon cancer cell lines harboring several different phenotypes (TP53 wild/mutant and KRAS or BRAF mutant). Here, BRAF is linked to malignant colon neoplasm.